TAS0953/HM06

· Taiho Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TAS0953/HM06, covering 2026-03-03 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities [Phase 1, Phase 2]

See pricing